Health Care • Biotechnology: Pharmaceutical Preparations
$431.16 ▲ +0.80
(+0.19%)
MKT CAP: $9.94B • VOL: 495.1K
52W L $399 52W H $615
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$362
MEDIAN
$483
MEAN
$492
HIGH
$586
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE MDGL TAPE
MDGL // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $521.70 | $495.83 | 2025-02-14 | $392.36 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $543.26 | $508.77 | 2025-02-06 | $405.29 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $491.52 | $474.28 | 2025-01-29 | $413.91 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $439.78 | — | 2025-01-17 | $422.54 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $379.42 | $409.60 | 2025-01-09 | $383.73 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $513.08 | $448.41 | 2024-12-18 | $375.11 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $418.23 | $435.47 | 2024-12-04 | $400.98 | -4.3% | 48% | C |